The Clone 3 Antibody secreted by the parent cell line created by the company must now be pharmaceutically produced in a form (called the "recombinant" antibody) that will ultimately be used in the treatment of patients.   A technical step -- achieved by producing a recombinant antibody protein -- is required to increase and standardize the pharmaceutical production of the monoclonal antibody.

    The required process -- to create the recombinant Clone 3 Antibody -- is accomplished by first isolating corresponding DNA from the parent cell line genomic blueprint which encodes to produce the existing monoclonal antibody and then  inserting the genetic code into a fast producing and FDA approved cell line. With this accomplished, the new cell line is then tested to confirm that it produces the same effective neutralizing effect on HIV isolates. 

     Once the recombinant antibody step to produce the pharmaceuitic grade protein has been completed, which can be achieved within a year, it will be followed immediately by animal trials and human trials -- leading to patient application.